Standard Operating Procedure for Ongoing Medical Surveillance of Subjects in BA/BE Studies
Department | BA-BE Studies |
---|---|
SOP No. | SOP/BA-BE/146/2025 |
Supersedes | SOP/BA-BE/146/2022 |
Page No. | Page 1 of 10 |
Issue Date | 17/04/2025 |
Effective Date | 20/04/2025 |
Review Date | 17/04/2026 |
1. Purpose
To establish a systematic approach for the ongoing medical surveillance of healthy volunteers participating in BA/BE studies to monitor their health status, ensure early detection of adverse events, and support protocol compliance.
2. Scope
This SOP applies to all clinical staff, including physicians, nurses, and coordinators, involved in the monitoring and care of subjects during the conduct of BA/BE trials from admission to final
follow-up.
3. Responsibilities
- Medical Officer: Perform routine clinical evaluations, document findings, and escalate medical issues promptly.
- Nursing Staff: Record vital signs, observe clinical changes, and report abnormalities to the Medical Officer.
- Study Coordinator: Ensure appropriate documentation and adherence to surveillance schedule.
- Principal Investigator (PI): Oversee medical management and subject well-being during study.
4. Accountability
The Clinical Unit Head is accountable for ensuring that all surveillance procedures are implemented effectively and any deviation is addressed through appropriate corrective measures.
5. Procedure
5.1 Pre-Dosing Surveillance
- Ensure that each subject undergoes:
- Medical history review
- Physical examination
- Vital signs assessment (BP, pulse, temperature, respiratory rate)
- ECG and lab reports (if applicable)
- Review findings and certify fitness for dosing in Annexure-1: Pre-Dose Medical Surveillance Log.
5.2 Dosing Day Surveillance
- On the day of dosing:
- Monitor fasting status of each subject
- Reassess vitals 30 minutes prior to dosing
- Record any last-minute medical complaints
- Post-dosing:
- Vitals at 1, 2, 4, 8, and 12 hours post-dose (or as per protocol)
- Clinical staff to observe for symptoms like dizziness, nausea, rash, or discomfort
- Document all observations in Annexure-2: Dosing Day Surveillance Chart
5.3 Residential Period Surveillance
- Conduct thrice-daily vitals checks (morning, afternoon, evening)
- Subjects to be asked about any discomfort, adverse symptoms, or sleep issues
- Monitor intake and output (food, water, urine) and document in Annexure-3: Daily Medical Monitoring Sheet
5.4 Post-Dosing and Follow-Up Surveillance
- On study exit:
- Perform exit medical evaluation
- Conduct pregnancy test (if applicable)
- Assess and document subject fitness to leave facility
- During follow-up:
- Collect lab samples as per protocol
- Check for delayed adverse reactions
- Record in Annexure-4: Follow-Up Medical Surveillance Log
5.5 Adverse Event (AE) Monitoring
- All AEs reported by subjects or detected during exams must be:
- Evaluated for severity and causality
- Documented in AE forms and Annexure-5: AE/SAE Surveillance Log
- Reported to Ethics Committee and sponsor (if required)
5.6 Medical Staff Deployment
- Ensure 24×7 availability of registered medical staff at the clinical site
- On-call physician must be reachable during outpatient follow-up hours
- Shift roster should be recorded in Annexure-6: Medical Duty Roster
5.7 Emergency Preparedness
- Emergency cart to be available and fully stocked during all study periods
- CPR-trained staff must be on-site during dosing and intensive surveillance windows
- Mock drills to be conducted quarterly and logged
6. Abbreviations
- BA/BE: Bioavailability/Bioequivalence
- PI: Principal Investigator
- ECG: Electrocardiogram
- AE: Adverse Event
- SAE: Serious Adverse Event
7. Documents
- Pre-Dose Medical Surveillance Log – Annexure-1
- Dosing Day Surveillance Chart – Annexure-2
- Daily Medical Monitoring Sheet – Annexure-3
- Follow-Up Medical Surveillance Log – Annexure-4
- AE/SAE Surveillance Log – Annexure-5
- Medical Duty Roster – Annexure-6
8. References
- ICH E6(R2) – Good Clinical Practice
- Schedule Y – Drugs and Cosmetics Rules, India
- WHO Guidelines for Clinical Trials
9. SOP Version
Version: 2.0
10. Approval Section
Prepared By | Checked By | Approved By | |
---|---|---|---|
Signature | |||
Date | |||
Name | |||
Designation | |||
Department |
11. Annexures
Annexure-1: Pre-Dose Medical Surveillance Log
Subject ID | Date | Vitals Normal | Complaints | Physician Comments |
---|---|---|---|---|
VOL1025 | 15/04/2025 | Yes | None | Fit for dosing |
Annexure-2: Dosing Day Surveillance Chart
Subject ID | Time | Vitals (BP/HR/Temp) | Observations | Initials |
---|---|---|---|---|
VOL1025 | 2h Post-dose | 120/78, 72, 36.8°C | No complaints | NV |
Annexure-3: Daily Medical Monitoring Sheet
Date | Subject ID | Morning | Afternoon | Evening | Remarks |
---|---|---|---|---|---|
16/04/2025 | VOL1025 | Stable | Stable | Stable | None |
Annexure-4: Follow-Up Medical Surveillance Log
Subject ID | Date | Visit Type | Vitals | Medical Issues |
---|---|---|---|---|
VOL1025 | 22/04/2025 | Follow-Up | Normal | None |
Annexure-5: AE/SAE Surveillance Log
Date | Subject ID | Event | Severity | Outcome |
---|---|---|---|---|
16/04/2025 | VOL1025 | Nausea | Mild | Resolved |
Annexure-6: Medical Duty Roster
Date | Shift | Doctor Name | Contact |
---|---|---|---|
15/04/2025 | Day | Dr. Sunita Reddy | 9876543210 |
Revision History:
Revision Date | Revision No. | Details | Reason | Approved By |
---|---|---|---|---|
01/01/2022 | 1.0 | Initial release | New SOP | QA Head |
17/04/2025 | 2.0 | Expanded procedure and added annexures | Audit and GCP alignment | QA Head |